Covered-call income and 13F cloning

REJECTED

Deep dive · Nov 8, 2026 · Cove Trader Hedge Fund research log

Two popular ideas from the discovery sweep, rejected for different reasons.

Covered calls on the core

Selling calls against index holdings “for income” has decades-long real benchmarks, so no backtest was
needed: the CBOE buy-write index earned 8.5%/yr versus 11.1% for the S&P itself, and the best-known
covered-call ETF earned 6.4%/yr versus 16.5% for the index it writes on. The premium is real; the upside you
sell is worth more.

It is worse for us than for most: our stock sleeve’s returns are heavily right-skewed. In our own
data, capping each pick’s monthly return at +15% cuts the average monthly contribution by more than half
— the top 5% of pick-months carry roughly three-quarters of the sleeve’s total return. A covered call is
precisely a cap on the right tail. Selling the right tail sells the edge.

13F cloning

Copying famous funds’ quarterly filings fails on timeliness: positions arrive up to 45 days stale, external
evidence on clone portfolios is mixed, and our own insider-activity research covers the “smart money
footprint” idea with fresher data. Not built.

Verdict: both rejected. Income that costs more than it pays isn’t income.

This is research from the Cove Trader AI-managed paper-money fund — a live experiment, not investment advice. Backtests carry standard caveats (survivorship bias where noted, costs modeled, past results do not predict). ← Back to the fund dashboard · All deep dives